Home / Pluripotent Stem Cells / Human Pluripotent Stem Cell Functional Identification Kit

Human Pluripotent Stem Cell Functional Identification Kit

Catalog #: SC027B
70 Citations Datasheet / COA / SDS
Catalog # Availability Size / Price Qty
SC027B
Verification of Induced Pluripotent Stem Cell Pluripotency.
5 Images
Product Details
Procedure
Citations (70)
FAQs
Reviews
Summary Product Datasheets Data Images Background

Human Pluripotent Stem Cell Functional Identification Kit Summary

Kit Summary

To verify pluripotency in human stem cells by in vitro functional differentiation.

Key Benefits

  • Verifies the pluripotency of your starting population
  • Only takes 5 days
  • Reduces experimental variation

 

Why functionally verify human stem cell pluripotency in vitro?

To determine if a cell is truly a pluripotent stem cell, it is important to verify its ability to differentiate into each of the three germ layers.

The teratoma assay is a standard way to assess pluripotency, but this method requires expensive animal models and is time-consuming, often requiring 6 to 10 weeks before pluripotency status can be determined. Similarly, embryoid body assays are time-consuming and rely on random differentiation.

  • Uses fully defined supplements to drive reproducible differentiation.
  • Provides results in 5 days to save time and reagents.
  • Avoids tissue embedding and sectioning procedures.
  • Can verify the ability to differentiate into 3 germ layers without the use of an animal model.
  • Verifies a healthy, pluripotent starting stem cell population to increase consistency between studies and reduce unwanted experimental variability.

 

Kit Contents

This kit contains the following specially formulated media supplements and growth factors to drive pluripotent stem cell differentiation and a marker to characterize each of the three germ layer cell types.

  • Differentiation Base Media Supplement (50X)
  • Ectoderm, Mesoderm, and Endoderm Differentiation Supplements
  • Ectoderm Marker: Goat Anti-Human Otx2 Antigen Affinity-purified Polyclonal Antibody
  • Mesoderm Marker: Goat Anti-Human Brachyury Antigen Affinity-purified Polyclonal AntibodyV
  • Endoderm Marker: Goat Anti-Human SOX17 Antigen Affinity-purified Polyclonal Antibody

The quantity of each component in this kit is sufficient to make 200 mL of media for differentiation. This is enough media for the differentiation of one 24-well plate of each cell type.

The acute and chronic effects of over-exposure to the reagents in this kit are unknown. Safe laboratory handling procedures should be followed and protective clothing should be worn when handling kit reagents.

 

Specifications

Source
N/A
Shipping Conditions
The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below.
Storage
Store the unopened product at -20 to -70 °C. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Do not use past expiration date.
Species
Human

Product Datasheets

You must select a language.

x
Product Datasheet
COA
SDS

Scientific Data

Immunocytochemistry Verification of Induced Pluripotent Stem Cell Pluripotency. View Larger

Verification of Induced Pluripotent Stem Cell Pluripotency. iPS2 human induced pluripotent stem cells were differentiated to ectoderm, mesoderm, and endoderm using the media supplements included in the Human Pluripotent Stem Cell Functional Identification Kit (Catalog # SC027). The kit also contains Goat Anti-Human Otx2 (ectoderm), Goat Anti-Human Brachyury (mesoderm), and Goat Anti-Human SOX17 (endoderm) Antigen Affinity-purified Polyclonal Antibodies for the confirmation of differentiation status. To further evaluate lineage commitment, cells were stained with a Goat Anti-Human SOX1 Antigen Affinity-purified Antibody (Catalog # AF3369), a Goat Anti-Human HAND1 Antigen Affinity-purified Antibody (Catalog # AF3168), and a Goat Anti-Human HNF-3 beta/FoxA2 Antigen Affinity-purified Antibody (Catalog # AF2400). The cells were stained using the NorthernLights™557-conjugated Donkey Anti-Goat IgG Secondary Antibody (Catalog # NL001; red) and the nuclei were counterstained with DAPI (blue). View our protocol for Fluorescent ICC Staining of Cells on Coverslips.

Cell Differentiation/ Maturation Analysis of Functional Tri-lineage Differentiation using Flow Cytometry. View Larger

Analysis of Functional Tri-lineage Differentiation using Flow Cytometry. JOY6 human induced pluripotent stem cells were differentiated to ectoderm, mesoderm, and endoderm using the Human Pluripotent Stem Cell Functional Identification Kit (R&D Systems, Catalog # SC027B). Differentiation was analyzed by flow cytometry using the protocol provided with this kit. Differentiated cells (orange) show increased expression of their respective lineage-specific markers (ectoderm - Otx2, mesoderm - Brachyury, endoderm - SOX17) compared to undifferentiated JOY6 pluripotent stem cells (blue).

Immunocytochemistry Verification of Human Embryonic Stem Cell Pluripotency. View Larger

Verification of Human Embryonic Stem Cell Pluripotency.
Human embryonic stem cells were differentiated to ectoderm, mesoderm, and endoderm using the media supplements included in the Human Pluripotent Stem Cell Functional Identification Kit (Catalog # SC027). The kit also contains Goat Anti-Human Otx2 (ectoderm), Goat Anti-Human Brachyury (mesoderm), and Goat Anti-Human SOX17 (endoderm) Antigen Affinity-purified Polyclonal Antibodies for the confirmation of differentiation status. The cells were stained using the NorthernLights™557-conjugated Donkey Anti-Goat IgG Secondary Antibody (Catalog # NL001; red) and the nuclei were counterstained with DAPI (blue). View our protocol for Fluorescent ICC Staining of Cells on Coverslips.

Cell Differentiation/ Maturation Verification of Human Induced Pluripotent Stem Cell Pluripotency. View Larger

Verification of Human Induced Pluripotent Stem Cell Pluripotency. Two human induced pluripotent stem cells lines (ADLF1 and FAB2) were differentiated to ectoderm, mesoderm, and endoderm using the media supplements included in the Human Pluripotent Stem Cell Functional Identification Kit (Catalog # SC027B). The kit also contains Goat Anti-Human Otx2 (ectoderm), Goat Anti-Human Brachyury (mesoderm), and Goat Anti-Human SOX17 (endoderm) Antigen Affinity-purified Polyclonal Antibodies for the confirmation of differentiation status. The cells were stained using the NorthernLights™ 557-conjugated Donkey Anti-Goat IgG Secondary Antibody (Catalog # NL001; red) and the nuclei were counterstained with DAPI (blue).

Assay Procedure

Refer to the product datasheet for complete product details.

Briefly, the pluripotency status of human stem cells is verified using the following in vitro differentiation procedure:

  • Culture pluripotent cells of interest
  • Induce endoderm, mesoderm, and ectoderm differentiation with media supplements
  • Evaluate differentiation using germ layer markers and fluorescent ICC
SC027 Protocol Graphic Summary
View Graphic Procedure
 

 

Kit Components

Reagents supplied in the Human Pluripotent Stem Cell Functional Identification Kit (Catalog # SC027B):

  • Differentiation Base Media Supplement (50X)
  • Ectoderm Differentiation Supplement
  • Mesoderm Differentiation Supplement
  • Endoderm Differentiation Supplement I
  • Endoderm Differentiation Supplement II
  • Ectoderm Marker: Goat Anti-Human Otx2 Antigen Affinity-purified Polyclonal Antibody
  • Mesoderm Marker: Goat Anti-Human Brachyury Antigen Affinity-purified Polyclonal Antibody
  • Endoderm Marker: Goat Anti-Human SOX17 Antigen Affinity-purified Polyclonal Antibody
     

    Note: The quantity of each component in this kit is sufficient to make 200 mL of medium for differentiation. This is enough medium for the differentiation of one 24-well plate for each lineage.

The quantity of each component in this kit is sufficient to differentiate two 24-well plates, or an equivalent surface area, of pluripotent stem cells into hepatocyte-like cells.

 

Other Supplies Required

Reagents

  • RPMI
  • BSA, very low endotoxin
  • D-MEM/F-12 (1X)
  • GlutaMAX™ (Invitrogen or equivalent)
  • Penicillin-Streptomycin
  • Phosphate Buffered Saline (PBS)
  • Trypan Blue Solution
  • MEF Conditioned Media (Catalog # AR005 or equivalent)
  • StemXVivo™ Culture Matrix (100X) (Catalog # CCM013), Cultrex® PathClear® BME Reduced Growth Factor Basement Membrane Extract (Catalog # 3433-005-01), or equivalent
  • Recombinant Human FGF basic (Tissue culture grade; Catalog # 4114-TC or equivalent)
  • Accutase® (Innovative Cell Technologies or equivalent)

Materials

  • Human pluripotent stem cells
  • 24-well culture plates
  • 15 mL centrifuge tubes
  • 50 mL centrifuge tubes
  • 0.2 μm syringe filter
  • 10 mL syringe
  • Pipettes and pipette tips
  • Serological pipettes

Equipment

  • 37 °C and 5% CO2 incubator
  • Centrifuge
  • Hemocytometer
  • Inverted microscope
  • 37 °C water bath

 

Procedure Overview

This protocol is designed for BG01V human embryonic stem (hES) cells and iPS2 human induced pluripotent stem (iPS) cells grown in Mouse Embryonic Fibroblast (MEF) Conditioned Media (Catalog # AR005). If using different cell lines or growth media, this protocol may need to be optimized.

Note: The quality of the human pluripotent cells used in the differentiation is imperative. Use of suboptimal quality or very high passage pluripotent cells can result in decreased differentiation efficiency and/or increased cell death.

Undifferentiated Cell Preparation

Add 1:100 Culture Matrix or Cultrex BME in sterile PBS.

Culture Matrix or Cultrex BME in sterile PBS

Add 1.1x105 cells/cm2 in MEF Conditioned Media containing 4 ng/mL FGF Basic.

MEF Conditioned Media containing 4 ng/mL FGF Basic
 

Differentiation Procedures

 

Ectoderm
Differentiation

Mesoderm
Differentiation

Endoderm
Differentiation
Day 1 Replace media with Ectoderm Differentiation Media. Replace media with
Mesoderm Differentiation Media.		 Replace media with Endoderm Differentiation Media.
Day 2 Repeat Repeat media change 12-16 hours later.
ICC detection of Brachyury (24-36 hours after initial differentiation)		 16-24 hours later, Replace media with Endoderm Differentiation Media II.
Day 3 Repeat   Replace media with Endoderm Differentiation Media II.
Day 4 ICC detection of Otx2.   ICC detection of SOX17.

Citations for Human Pluripotent Stem Cell Functional Identification Kit

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

70 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. Generation of Marfan syndrome-specific induced pluripotent stem cells harboring FBN1 mutations
    Authors: Vacante, F;Venkateshappa, R;Htet, M;Yan, C;Wu, JC;
    Stem cell research  2024-10-01
  2. Generation of two induced pluripotent stem cell lines from patients with Li-Fraumeni Syndrome carrying TP53 mutation
    Authors: Sun, J;Ren, L;Canel Rivero, G;Xu, L;Ladabaum, U;C Wu, J;
    Stem cell research  2024-08-03
  3. Generation of two induced pluripotent stem cell lines from patients with Williams syndrome
    Authors: Dai, Y;Zhu, W;Flores Banuelos, AG;Li, J;Mukherjee, S;Algaze, C;Wu, JC;
    Stem cell research  2024-08-01
  4. Generation of two familial hypercholesterolemia patient-specific induced pluripotent stem cell lines harboring heterozygous mutations in the LDLR gene
    Authors: Gao, J;Li, J;Xu, L;Yan, CD;Knowles, JW;Wu, JC;
    Stem cell research  2024-06-04
  5. Generating human AMN and cALD iPSC-derived astrocytes with potential for modeling X-linked adrenoleukodystrophy phenotypes
    Authors: Kaur, N;Singh, J;
    bioRxiv : the preprint server for biology  2024-06-01
  6. Generation of iPSC line NCHi015-A from a patient with truncus arteriosus carrying heterozygous variants in KMT2D and NOTCH1
    Authors: Wang, J;Bering, J;Alonzo, M;Ye, S;Texter, K;Garg, V;Zhao, MT;
    Stem cell research  2024-05-29
  7. Impaired Relaxation in Induced Pluripotent Stem Cell-Derived Cardiomyocytes with Pathogenic TNNI3 Mutation of Pediatric Restrictive Cardiomyopathy
    Authors: Wang, R;Hasegawa, M;Suginobe, H;Yoshihara, C;Ishii, Y;Ueyama, A;Ueda, K;Hashimoto, K;Hirose, M;Ishii, R;Narita, J;Watanabe, T;Kawamura, T;Taira, M;Ueno, T;Miyagawa, S;Ishida, H;
    Journal of the American Heart Association  2024-03-19
  8. Generation of two induced pluripotent stem cell lines from healthy patients of African American ancestry
    Authors: Mullen, M;Kojic, A;Alamana, C;Canel, G;Lai, C;Knowles, JW;Wu, JC;
    Stem cell research  2024-02-10
  9. Generation of five induced pluripotent stem cell lines from patients with MECP2 Duplication Syndrome
    Authors: Mendonca, D;Cappuccio, G;Sheppard, J;Delacruz, M;Bengtsson, J;Carvalho, CMB;Bajic, A;Park, H;Kim, JJ;Jafar-Nejad, P;Coquery, C;Pehlivan, D;Suter, B;Maletic-Savatic, M;
    Stem cell research  2023-12-21
  10. Generation and characterization of a human induced pluripotent stem cell line heterozygous for a NOTCH1 mutation (NCHi014-A)
    Authors: Aljuhani, M;Choudhury, TZ;Yu, Y;Ye, S;Zhao, M;Garg, V;
    Stem cell research  2023-12-14
  11. Generation of two induced pluripotent stem cell lines from hereditary amyloidosis patients with polyneuropathy carrying heterozygous transthyretin (TTR) mutation
    Authors: Melesio, J;Bonilauri, B;Li, A;Pang, PD;Liao, R;Witteles, RM;Wu, JC;Sallam, K;
    Stem cell research  2023-11-29
  12. Generation of two induced pluripotent stem cell lines from patients suffering from pulmonary hypertension
    Authors: Chen, G;Orozco, L;Parmisano, S;Jahng, JWS;Vera, CD;Zhuge, Y;Wu, JC;Obal, D;
    Stem cell research  2023-09-30
  13. Generation and characterization of induced pluripotent stem cells from a Parkinson's disease patient carrying the digenic LRRK2 p.G2019S and GBA1 p.N409S mutations
    Authors: Oleksy, C;Massart, F;Goldwurm, S;Arado, A;Arena, G;Boussaad, I;Krüger, R;
    Stem cell research  2023-09-28
  14. Generation of two induced pluripotent stem cell lines from patients with cardiac amyloidosis carrying heterozygous transthyretin (TTR) mutation
    Authors: Bonilauri, B;Shin, HS;Htet, M;Yan, CD;Witteles, RM;Sallam, K;Wu, JC;
    Stem cell research  2023-09-27
  15. Characterization of an induced pluripotent stem cell line NCHi011-A from a 23-year-old female with Alagille Syndrome harboring a heterozygous JAG1 pathogenic variant
    Authors: Stanberry, I;Cunningham, D;Ye, S;Alonzo, M;Zhao, MT;Garg, V;Lilly, B;
    Stem cell research  2023-09-23
  16. Generation of two induced pluripotent stem cell lines from Duchenne muscular dystrophy patients
    Authors: Liu, W;Zeng, W;Kong, X;Htet, M;Yu, R;Wheeler, M;Day, JW;Wu, JC;
    Stem cell research  2023-09-18
  17. Generation of two induced pluripotent stem cell lines from catecholaminergic polymorphic ventricular tachycardia patients carrying RYR2 mutations
    Authors: Kong, X;Belbachir, N;Zeng, W;Yan, CD;Navada, S;Perez, MV;Wu, JC;
    Stem cell research  2023-05-12
  18. Generation of two induced pluripotent stem cell lines from spinal muscular atrophy type 1 patients carrying no functional copies of SMN1 gene
    Authors: W Zeng, X Kong, C Alamana, Y Liu, J Guzman, PD Pang, JW Day, JC Wu
    Stem Cell Research, 2023-04-17;69(0):103095.  2023-04-17
  19. Generation of three induced Pluripotent Stem Cell lines from individuals with Hypomyelination with Atrophy of Basal Ganglia and Cerebellum caused by a c.745G>A (p.D249N) autosomal dominant mutation in TUBB4A
    Authors: AA Almad, L Garcia, A Takanohash, A Gagne, W Yang, J Ann McGuir, D French, A Vanderver
    Stem Cell Research, 2023-03-26;69(0):103083.  2023-03-26
  20. Generation of two induced pluripotent stem cell lines and the corresponding isogenic controls from Parkinson's disease patients carrying the heterozygous mutations c.1290A�>�G (p.T351A) or c.2067A�>�G (p.T610A) in the RHOT1 gene encoding Miro1
    Authors: A Chemla, G Arena, C Saraiva, C Berenguer-, D Grossmann, A Grünewald, C Klein, P Seibler, JC Schwamborn, R Krüger
    Stem Cell Research, 2023-03-25;69(0):103085.  2023-03-25
  21. Establishment of TUBB3-mCherry knock-in human pluripotent stem cell line using CRISPR/Cas9 (SNUe003-A-4)
    Authors: AH Kim, HM Lee, HS Kim, J Jung, H Seol, E Choi, S Lee, Y Min Choi, JK Jun, HS Kim, J Jang
    Stem Cell Research, 2023-03-08;69(0):103064.  2023-03-08
  22. Identification of cell-biologic mechanisms of coronary artery spasm and its ex vivo diagnosis using peripheral blood-derived iPSCs
    Authors: HM Yang, JE Lee, JY Kim, J You, J Kim, HS Lee, HM Yoo, MG Kong, JK Han, HJ Cho, KW Park, HJ Kang, BK Koo, YB Park, HS Kim
    Biomaterials research, 2023-02-18;27(1):16.  2023-02-18
  23. High-Efficiency CRISPR/Cas9-Mediated Correction of a Homozygous Mutation in Achromatopsia-Patient-Derived iPSCs
    Authors: L Siles, P Gaudó, E Pomares
    International Journal of Molecular Sciences, 2023-02-11;24(4):.  2023-02-11
  24. Establishment of NCHi009-A, an iPSC line from a patient with hypoplastic left heart syndrome (HLHS) carrying a heterozygous NOTCH1 mutation
    Authors: S Adhicary, S Ye, H Lin, K Texter, V Garg, MT Zhao
    Stem Cell Research, 2022-12-31;66(0):103013.  2022-12-31
  25. Generation of two iPSC lines from long QT syndrome patients carrying SNTA1 variants
    Authors: N Jimenez-Te, CD Vera, Z Yildirim, J Vicente Gu, T Zhang, JC Wu
    Stem Cell Research, 2022-12-12;66(0):103003.  2022-12-12
  26. Generation and characterization of a human induced pluripotent stem cell (iPSC) line from a patient with congenital heart disease (CHD)
    Authors: H Lin, SQ Ye, ZH Xu, JS Penaloza, M Aljuhani, T Vetter, MT Zhao, KL McBride
    Stem Cell Research, 2022-10-31;65(0):102958.  2022-10-31
  27. Generation of two induced pluripotent stem cell lines from dilated cardiomyopathy patients caused by heterozygous mutations in the HCN4 gene
    Authors: Z Yildirim, A Kojic, CD Yan, MA Wu, R Vagelos, JC Wu
    Stem Cell Research, 2022-10-19;65(0):102951.  2022-10-19
  28. Generation of two induced pluripotent stem cell lines from dilated cardiomyopathy patients carrying heterozygous FLNC mutations
    Authors: A Kojic, H Kim, JV Guevara, S Ravada, K Sallam, JC Wu
    Stem Cell Research, 2022-09-26;64(0):102928.  2022-09-26
  29. Generation of an induced pluripotent stem cell line NCHi003-A from a 11-year-old male with pulmonary atresia with intact ventricular septum (PA-IVS)
    Authors: J Contreras, M Alonzo, S Ye, H Lin, L Hernandez-, KL McBride, K Texter, V Garg, MT Zhao
    Stem Cell Research, 2022-08-10;64(0):102893.  2022-08-10
  30. Characterization of an iPSC line NCHi006-A from a patient with hypoplastic left heart syndrome (HLHS)
    Authors: M Alonzo, J Contreras, S Ye, H Lin, L Hernandez-, KL McBride, K Texter, V Garg, MT Zhao
    Stem Cell Research, 2022-08-09;64(0):102892.  2022-08-09
  31. Generation of a human induced pluripotent stem cell line carrying the TYR c.575C>A (p.Ser192Tyr) and c.1205G>A (p.Arg402Gln) variants in homozygous state using CRISPR-Cas9 genome editing
    Authors: J Liu, GC Black, SJ Kimber, PI Sergouniot
    Stem Cell Research, 2022-07-30;64(0):102880.  2022-07-30
  32. Generation of human induced pluripotent stem cell lines carrying heterozygous PLN mutation from dilated cardiomyopathy patients
    Authors: A Caudal, G Mondejar-P, CD Vera, DR Williams, SP Shenoy, D Liang, JC Wu
    Oncogene, 2022-07-11;63(0):102855.  2022-07-11
  33. Generation of isogenic control DJ-1-delP GC13 for the genetic Parkinson's disease-patient derived iPSC line DJ-1-delP (LCSBi008-A-1)
    Authors: P Mencke, Z Hanss, J Jarazo, F Massart, A Rybicki, E Petkovski, E Glaab, I Boussaad, V Bonifati, J Christian, W Mandemaker, R Krüger
    Stem Cell Research, 2022-05-17;62(0):102815.  2022-05-17
  34. Generation and characterization of a genetic Parkinson's disease-patient derived iPSC line DJ-1-delP (LCSBi008-A)
    Authors: P Mencke, I Boussaad, G Önal, AJA Kievit, AJW Boon, W Mandemaker, V Bonifati, R Krüger
    Stem Cell Research, 2022-04-26;62(0):102792.  2022-04-26
  35. Generation of alphaMHC-EGFP knock-in in human pluripotent stem cell line, SNUe003-A-3 using CRISPR/Cas9-based gene targeting
    Authors: HM Lee, AH Kim, S Hwang, J Jung, H Seol, JJ Sung, SM Jeong, YM Choi, JK Jun, HS Kim, J Jang
    Stem Cell Research, 2022-04-04;61(0):102779.  2022-04-04
  36. Elimination of Reprogramming Transgenes Facilitates the Differentiation of Induced Pluripotent Stem Cells into Hepatocyte-like Cells and Hepatic Organoids
    Authors: J Jeong, TH Kim, M Kim, YK Jung, KS Kim, S Shim, H Jang, WI Jang, SB Lee, D Choi
    Biology, 2022-03-23;11(4):.  2022-03-23
  37. Heterozygous LMNA mutation-carrying iPSC lines from three cardiac laminopathy patients
    Authors: S Cho, C Lee, C Lai, Y Zhuge, F Haddad, M Fowler, K Sallam, JC Wu
    Stem Cell Research, 2022-01-03;59(0):102657.  2022-01-03
  38. Derivation and characterization of the induced pluripotent stem cell line CUIMCi004-A from a patient with a novel frameshift variant in exon 18a of OCRL
    Authors: G Iannello, A Patel, D Sirabella, B Corneo, VV Thaker
    Stem Cell Research, 2021-12-23;59(0):102635.  2021-12-23
  39. Generation of three iPSC lines from dilated cardiomyopathy patients carrying a pathogenic LMNA variant
    Authors: C Lee, S Cho, C Lai, S Shenoy, R Vagelos, JC Wu
    Stem Cell Research, 2021-12-21;59(0):102638.  2021-12-21
  40. Generation of two induced pluripotent stem cell lines from Brugada syndrome affected patients carrying SCN5A mutations
    Authors: N Belbachir, C Lai, JW Rhee, Y Zhuge, MV Perez, K Sallam, JC Wu
    Stem Cell Research, 2021-11-23;57(0):102605.  2021-11-23
  41. Generation of three induced pluripotent stem cell lines (SCVIi014-A, SCVIi015-A, and SCVIi016-A) from patients with LQT1 caused by heterozygous mutations in the KCNQ1 gene
    Authors: H Zhang, JWS Jahng, Y Liu, AJ Chase, MV Perez, JC Wu
    Stem Cell Research, 2021-08-05;55(0):102492.  2021-08-05
  42. Generation of one control and four iPSCs clones from patients with Emery-Dreifuss muscular dystrophy type 1
    Authors: M Machowska, C Bearzi, K Piekarowic, I ?aczma?ska, R Rzepecki
    Stem Cell Research, 2021-08-05;55(0):102487.  2021-08-05
  43. Generation of three induced pluripotent stem cell lines from hypertrophic cardiomyopathy patients carrying MYH7 mutations
    Authors: X Cao, JWS Jahng, C Lee, Y Zha, MT Wheeler, K Sallam, JC Wu
    Stem Cell Research, 2021-07-12;55(0):102455.  2021-07-12
  44. Generation of the iPSC line CUIMCi003-A derived from a patient with severe early onset obesity
    Authors: G Iannello, A Patel, D Sirabella, B Corneo, V Thaker
    Stem Cell Research, 2021-06-21;54(0):102432.  2021-06-21
  45. Neurogenic and Neuroprotective Potential of Stem/Stromal Cells Derived from Adipose Tissue
    Authors: A Figiel-Dab, K Radoszkiew, P Rybkowska, NE Krzesniak, D Sulejczak, A Sarnowska
    Cells, 2021-06-11;10(6):.  2021-06-11
  46. Generation of three induced pluripotent stem cell lines, SCVIi003-A, SCVIi004-A, SCVIi005-A, from patients with ARVD/C caused by heterozygous mutations in the PKP2 gene
    Authors: JWS Jahng, KE Black, L Liu, HR Bae, M Perez, EA Ashley, K Sallam, JC Wu
    Stem Cell Research, 2021-03-12;53(0):102284.  2021-03-12
  47. Integrated, automated maintenance, expansion and differentiation of 2D and 3D patient-derived cellular models for high throughput drug screening
    Authors: I Boussaad, G Cruciani, S Bolognin, P Antony, CM Dording, YJ Kwon, P Heutink, E Fava, JC Schwamborn, R Krüger
    Scientific Reports, 2021-01-14;11(1):1439.  2021-01-14
  48. Induced organoids derived from patients with ulcerative colitis recapitulate colitic reactivity
    Authors: SK Sarvestani, S Signs, B Hu, Y Yeu, H Feng, Y Ni, DR Hill, RC Fisher, S Ferrandon, RK DeHaan, J Stiene, M Cruise, TH Hwang, X Shen, JR Spence, EH Huang
    Nature Communications, 2021-01-11;12(1):262.  2021-01-11
  49. YAP-TEAD1 control of cytoskeleton dynamics and intracellular tension guides human pluripotent stem cell mesoderm specification
    Authors: S Pagliari, V Vinarsky, F Martino, AR Perestrelo, J Oliver De, G Caluori, J Vrbsky, P Mozetic, A Pompeiano, A Zancla, SG Ranjani, P Skladal, D Kytyr, Z Zdráhal, G Grassi, M Sampaolesi, A Rainer, G Forte
    Cell Death Differ, 2020-10-28;0(0):.  2020-10-28
  50. The lncRNA H19 alleviates muscular dystrophy by stabilizing dystrophin
    Authors: Y Zhang, Y Li, Q Hu, Y Xi, Z Xing, Z Zhang, L Huang, J Wu, K Liang, TK Nguyen, SD Egranov, C Sun, Z Zhao, DH Hawke, J Li, D Sun, JJ Kim, P Zhang, J Cheng, A Farida, MC Hung, L Han, R Darabi, C Lin, L Yang
    Nat Cell Biol, 2020-10-26;22(11):1332-1345.  2020-10-26
  51. Using High-Content Screening to Generate Single-Cell Gene-Corrected Patient-Derived iPS Clones Reveals Excess Alpha-Synuclein with Familial Parkinson's Disease Point Mutation A30P
    Authors: P Barbuti, P Antony, B Santos, F Massart, G Cruciani, C Dording, J Arias, J Schwamborn, R Krüger
    Cells, 2020-09-10;9(9):.  2020-09-10
  52. Generation of two iPS cell lines (HIHDNDi001-A and HIHDNDi001-B) from a Parkinson�s disease patient carrying the heterozygous p.A30P mutation in SNCA
    Authors: PA Barbuti, BFR Santos, CM Dording, G Cruciani, F Massart, A Hummel, R Krüger
    Stem Cell Res, 2020-08-08;48(0):101951.  2020-08-08
  53. Induced pluripotent stem cell line (INSAi002-A) from a Fabry Disease patient hemizygote for the rare p.W287X mutation
    Authors: AJ Duarte, D Ribeiro, R Santos, L Moreira, J Bragança, O Amaral
    Stem Cell Res, 2020-04-20;45(0):101794.  2020-04-20
  54. Induced pluripotent stem cell line (LCSBi001-A) derived from a patient with Parkinson's disease carrying the p.D620N mutation in VPS35
    Authors: SB Larsen, Z Hanss, G Cruciani, F Massart, PA Barbuti, G Mellick, R Krüger
    Stem Cell Res, 2020-04-04;45(0):101776.  2020-04-04
  55. Generation of a knock-in MAP2-tdTomato reporter human embryonic stem cell line with inducible expression of NEUROG2/1 (NYGCe001-A)
    Authors: C Lu, NE Sanjana
    Stem Cell Res, 2019-11-01;41(0):101643.  2019-11-01
  56. Induced pluripotent stem cell line (INSAi001-A) from a Gaucher disease type 3 patient compound heterozygote for mutations in the GBA1 gene
    Authors: AJ Duarte, D Ribeiro, R Santos, L Moreira, J Bragança, O Amaral
    Stem Cell Res, 2019-10-18;41(0):101595.  2019-10-18
  57. Organoid single-cell genomic atlas uncovers human-specific features of brain development
    Authors: S Kanton, MJ Boyle, Z He, M Santel, A Weigert, F Sanchís-Ca, P Guijarro, L Sidow, JS Fleck, D Han, Z Qian, M Heide, WB Huttner, P Khaitovich, S Pääbo, B Treutlein, JG Camp
    Nature, 2019-10-16;574(7778):418-422.  2019-10-16
  58. Establishment of PITX3-mCherry knock-in reporter human embryonic stem cell line (WAe009-A-23)
    Authors: S Park, JE Yoo, DR Lee, J Jang, MS Cho, DS Kim, DW Kim
    Stem Cell Res, 2019-07-18;39(0):101499.  2019-07-18
  59. Generation of Spinocerebellar Ataxia Type 2 induced pluripotent stem cell lines, CHOPi002-A and CHOPi003-A, from patients with abnormal CAG repeats in the coding region of the ATXN2 gene
    Authors: JA Maguire, AL Gagne, P Gonzalez-A, BL Davidson, V Shakkottai, P Gadue, DL French
    Stem Cell Res, 2018-12-10;34(0):101361.  2018-12-10
  60. Generation of a human Juvenile myelomonocytic leukemia iPSC line, CHOPi001-A, with a mutation in CBL
    Authors: AL Gagne, JA Maguire, S Gandre-Bab, ST Chou, SK Tasian, ML Loh, MJ Weiss, P Gadue, DL French
    Stem Cell Res, 2018-07-05;31(0):157-160.  2018-07-05
  61. Atorvastatin Inhibits the HIF1?-PPAR Axis, Which Is Essential for Maintaining the Function of Human Induced Pluripotent Stem Cells
    Authors: Y Nakashima, C Miyagi-Shi, H Noguchi, T Omasa
    Mol. Ther., 2018-06-19;0(0):.  2018-06-19
  62. Inducible overexpression of RUNX1b/c in human embryonic stem cells blocks early hematopoiesis from mesoderm.
    Authors: Chen B, Teng J, Liu H, Pan X, Zhou Y, Huang S, Lai M, Bian G, Mao B, Sun W, Zhou Q, Yang S, Nakahata T, Ma F
    J Mol Cell Biol, 2017-08-01;9(4):262-273.  2017-08-01
  63. Cord blood cell-derived iPSCs as a new candidate for chondrogenic differentiation and cartilage regeneration
    Authors: Y Nam, YA Rim, SM Jung, JH Ju
    Stem Cell Res Ther, 2017-01-28;8(1):16.  2017-01-28
  64. Recapitulation of Clinical Individual Susceptibility to Drug-Induced QT Prolongation in Healthy Subjects Using iPSC-Derived Cardiomyocytes
    Authors: T Shinozawa, K Nakamura, M Shoji, M Morita, M Kimura, H Furukawa, H Ueda, M Shiramoto, K Matsuguma, Y Kaji, I Ikushima, M Yono, SY Liou, H Nagai, A Nakanishi, K Yamamoto, S Izumo
    Stem Cell Reports, 2017-01-19;0(0):.  2017-01-19
  65. Human-induced pluripotent stem cell-derived cardiomyocytes from cardiac progenitor cells: effects of selective ion channel blockade
    Authors: Claudia Altomare
    Europace, 2016-12-01;18(0):iv67-iv76.  2016-12-01
  66. Toll-like receptor 2 is increased in neurons in Parkinson's disease brain and may contribute to alpha-synuclein pathology
    Authors: Glenda M Halliday
    Acta Neuropathol., 2016-11-25;0(0):.  2016-11-25
  67. The Generation of Human Induced Pluripotent Stem Cells from Blood Cells: An Efficient Protocol Using Serial Plating of Reprogrammed Cells by Centrifugation
    Stem Cells Int, 2016-08-04;2016(0):1329459.  2016-08-04
  68. Characteristics of bovine inner cell mass-derived cell lines and their fate in chimeric conceptuses.
    Authors: Furusawa, Tadashi, Ohkoshi, Katsuhir, Kimura, Koji, Matsuyama, Shuichi, Akagi, Satoshi, Kaneda, Masahiro, Ikeda, Mitsumi, Hosoe, Misa, Kizaki, Keiichir, Tokunaga, Tomoyuki
    Biol Reprod, 2013-08-08;89(2):28.  2013-08-08
  69. Cholesterol-secreting and statin-responsive hepatocytes from human ES and iPS cells to model hepatic involvement in cardiovascular health.
    Authors: Krueger, Winfried, Tanasijevic, Borko, Barber, Vanessa, Flamier, Anthony, Gu, Xinsheng, Manautou, Jose, Rasmussen, Theodore
    PLoS ONE, 2013-07-11;8(7):e67296.  2013-07-11
  70. Treatment with small molecules is an important milestone towards the induction of pluripotency in neural stem cells derived from human cord blood.
    Authors: Szablowska-Gadomska, Ilona, Sypecka, Joanna, Zayat, Valery, Podobinska, Martyna, Pastwinska, Anna, Pienkowska-Grela, Barbara, Buzanska, Leonora
    Acta Neurobiol Exp (Wars), 2012-01-01;72(4):337-50.  2012-01-01

FAQs

No product specific FAQs exist for this product, however you may

View all Stem Cell Product FAQs

Reviews for Human Pluripotent Stem Cell Functional Identification Kit

There are currently no reviews for this product. Be the first to review Human Pluripotent Stem Cell Functional Identification Kit and earn rewards!

Have you used Human Pluripotent Stem Cell Functional Identification Kit?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review